Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Biopsy/resection Clear all
Completed No phase listed Observational

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

NCT01393483
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma
Interventions
serum and tissue mesothelin
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Early Phase 1 Interventional

Fimepinostat in Treating Brain Tumors in Children and Young Adults

NCT03893487
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
Interventions
Fimepinostat, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
3 Years to 39 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

Sentinel Lymph Node Biopsy Using Peritumoral Injection With Blue Dye Confirmation

NCT00575744
View directory record Official record
Conditions
Breast Cancer
Interventions
Sentinel Node Biopsy
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Phase 1 Interventional

RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)

NCT06389591
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1), RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)
Biological
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

NCT04959474
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
Interventions
Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection
Other · Radiation · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional Results available

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

NCT01305772
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Panitumumab, Surgery, Radiation Therapy
Drug · Procedure
Lead sponsor
Neal Ready
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 3 Interventional

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

NCT06724237
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
164
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Enrolling by invitation Phase 1 Interventional

Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea

NCT01868373
View directory record Official record
Conditions
Active C. Difficile Colitis
Interventions
Microbiota Transplantation (FMT)
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 21, 2026, 5:39 AM EDT
Not yet recruiting Early Phase 1 Interventional

Oral Gallium Maltolate for Recurrent Glioblastoma

NCT07515924
View directory record Official record
Conditions
Glioblastoma
Interventions
Gallium Maltolate, Surgical Intervention
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Withdrawn Phase 3 Interventional

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

NCT01826864
View directory record Official record
Conditions
Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
Interventions
sargramostim, sentinel lymph node biopsy, laboratory biomarker analysis, hypertonic saline
Biological · Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

NCT01208974
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma
Interventions
Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery, Prophylactic Nipple-Areolar Complex RT
Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

GI Neuromuscular Pathology Prospective Registry

NCT02165059
View directory record Official record
Conditions
Gastroparesis
Interventions
Surgical Full Thickness Biopsy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
6 Months to 90 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated No phase listed Observational

Liver and Biliary Tumor Tissue Registry

NCT02917759
View directory record Official record
Conditions
Hepatocellular Carcinoma, Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

NCT03532217
View directory record Official record
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Interventions
PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis
Biological · Drug · Device + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 21, 2026, 5:39 AM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ

NCT02908178
View directory record Official record
Conditions
Ductal Carcinoma In Situ
Interventions
Sentinel lymph node biopsy (SLNB)
Procedure
Lead sponsor
Yale University
Other
Eligibility
67 Years to 94 Years · Female only
Enrollment
28,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1Phase 2 Interventional

Percutaneous Removal and Margin Ablation for Breast Cancer

NCT00574301
View directory record Official record
Conditions
Breast Cancer
Interventions
Percutaneous Removal and Margin Ablation
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 1 Interventional

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

NCT06357377
View directory record Official record
Conditions
Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
Interventions
NEO100
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 3 Interventional

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

NCT04722692
View directory record Official record
Conditions
DCIS, Breast Cancer, Breast Neoplasms, Sentinel Lymph Node
Interventions
Delayed SLND, Late SLND
Diagnostic Test
Lead sponsor
Uppsala University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 21, 2026, 5:39 AM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Suspended Phase 1 Interventional

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

NCT06447987
View directory record Official record
Conditions
Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Cetuximab, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Results available

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

NCT03258593
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Not applicable Interventional

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

NCT02385214
View directory record Official record
Conditions
Cutaneous Melanoma by AJCC V7 Stage
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 21, 2026, 5:39 AM EDT